Industry intelligence for the people who run hormone, peptide, and GLP-1 clinics. One read, then back to work.
3 items. 4-minute read.
Lead story
PCAC backs six of seven; votes are advisory, list unmoved
FDA's Pharmacy Compounding Advisory Committee finished its two-day peptide review on July 24 recommending six of the seven substances in front of it for the 503A Bulk Drug Substances list. Day one cleared BPC-157, TB-500, KPV, and MOTS-c, per FDA Law Blog on July 24. Day two added Semax and Epitalon and rejected emideltide, better known as DSIP, on a 6-7 vote, per STAT.
The committee is advisory. FDA decides whether to add the substances through notice-and-comment rulemaking, and nothing from the meeting sets a date for that. Until a final rule places a substance on the list, a 503A pharmacy compounding with it stands exactly where it stood last week, whatever this week's headlines imply.
The business risk is the gap between those two facts. Patients and competitors will read "approved," and some clinics will market as if the rule already exists.
The panel also went against FDA's own reviewers, who had recommended adding none of the seven, per RAPS. What changes the read is a proposed rule in the Federal Register. Until one appears, this is momentum, not authorization, and the distance between a vote and a final rule has historically been measured in years, not weeks.
Our take. Six recommendations in one session, over the objection of the agency's own reviewers, is the strongest committee signal the 503A lane has produced in years, and it moves the constraint from panel sentiment to FDA's rulemaking pace. The single no matters as much as the six yeses: it says the panel is reading nominations on their files rather than voting the category. We want useful compounds reaching the list on the strength of their data, and votes like these are how that happens; they are still not the list.
Do this next. Is anyone on your team drafting copy around "approved"? Hold every claim tied to this week's votes until a final rule lands, and have counsel review anything that implies these substances are compoundable today.
The Signal
Business
Oral GLP-1 obesity prescriptions climb at both Novo and Lilly
Fierce Pharma launched a weekly Oral GLP-1 Tracker on July 25, built on IQVIA prescription data and analyst notes, to follow Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo as they compete for the oral weight-loss market. The debut edition reports obesity prescriptions climbing for both drugs.
Both rising at once is the detail that matters. That pattern points to market expansion, not share-trading: the orals are pulling in patients who wanted the outcome without the injection, a population that may never have booked a weight-loss consult at all.
For a clinic built on injectable GLP-1 programs, a public weekly scoreboard changes the conversation in the exam room. Patients will arrive having read which pill is winning, and the pharma reps calling on your referring prescribers will be reading the same chart.
Do this next. Do you know how many consults you lose at the needle? Start logging needle aversion as a distinct lost-consult reason this week, so you can measure the oral pull in your own funnel instead of reading about it in a tracker.
Compounding & Bulks
What the one rejection tells you about the next nomination
The emideltide vote was the panel's only negative in two days of peptide reviews. Fierce Pharma reports panelists cited low-quality efficacy evidence, poor characterization of the bulk substance, and the existence of approved therapies for every proposed use.
Those three reasons are the standard the committee applied when it said no, and they are the standard the next nomination gets measured against.
For operators, the read is simple: this panel is not waving the peptide slate through as a category. Each nomination is getting its own vote on its own file, and a substance that draws a no is a substance whose compounding future got materially worse.
Do this next. Is anything on your menu still waiting on a vote or on FDA's final list decision? Make that list today and flag which revenue lines depend on a substance that has not cleared either step.
Also on the wire
UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm. An FDA advisory committee has recommended that three peptide drugs that were previously restricted because of potential safety concerns be restored to the 503A Bulk Drug Substances list, which would remove the limits on how they are produced by compounders. Fierce Pharma
FDA Advisory Committee Recommends Adding BPC-157 to Compounding List. A closely watched FDA advisory committee has voted to recommend adding BPC-157 to the list of bulk drug substances that may be used by traditional compounding pharmacies, marking a potentially significant development for providers who have followed growing interest in peptide therapies. AmSpa
STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides. The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides. STAT
FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157. An FDA advisory committee voted Thursday to recommend expanding access to a popular peptide used by health and wellness enthusiasts for repairing muscles and healing injuries. Endpoints News
New IV Rules in Maine. The Maine Boards of Medicine, Osteopathic Medicine, and Nursing have adopted a joint rule which covers medical spas and IV therapy practices. AmSpa
Forward this to an operator who needs it.
Filed by the ODR desk.
Corrections: [email protected]. Fixes run at the top of the next issue.
How we source and correct: https://go.optimized.news/standards.html
ODR is industry intelligence, not legal or medical advice. Decisions about your practice belong with your counsel and your medical director.